Navigation Links
Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
Date:9/9/2010

CAMBRIDGE, Mass. and BOTHELL, Wash., Sept. 9 /PRNewswire/ -- Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

(Logo:  http://photos.prnewswire.com/prnh/20100909/SF59797LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100909/SF59797LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20100824/SF54816LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100824/SF54816LOGO)

CMC Biologics was selected by Edimer for their lead product due to its depth of expertise in protein development, analytical development and its cGMP manufacturing capabilities.

Neil Kirby, Ph.D., Edimer CEO, commented, "CMC's extensive experience in the GMP manufacture of therapeutic proteins makes them an ideal company to help us move this product forward. We believe that this product has the potential for making a difference in individuals' lives that currently have no available therapeutic options."

Gustavo Mahler, Ph.D., CMC Biologics Chief Operating Officer noted, "CMC is delighted to be able to assist Edimer in the development and production of this orphan protein. Our two teams are working together in an open and collaborative manner and we are excited about the project's potential."

About EDI200

Ectodysplasin-A1 (EDA-A1) is a signaling protein expressed in healthy individuals that is involved in the formation of sweat glands, teeth, hair and certain glandular structures. This protein is missing in patients with XLHED.  EDI200 is a form of EDA-A1 being developed by Edimer as a treatment for certain patients with XLHED.  EDI200 has been shown to substitute for lack of functional EDA-A1 protein in mouse and dog models of XLHED.

About Edimer Pharmaceuticals

Edimer Pharmaceuticals (www.edimerpharma.com)

Edimer is dedicated to deliver a significant and durable improvement in the health and quality of life to future generations affected by XLHED. Edimer was established in 2009 based on research conducted at the University of Lausanne, Switzerland. Edimer's lead product candidate, EDI200, represents the first of a new class of molecules designed to correct a developmental disorder in a pediatric population.

About CMC

CMC Biologics (www.cmcbio.com) is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, from its facilities in Copenhagen, Denmark, and Seattle, WA.  The company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production.  CMC Biologics' wide range of integrated services includes cell line development using its proprietary CHEF1® system, process development and comprehensive analytical testing.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes.  


'/>"/>
SOURCE Edimer Pharmaceuticals; CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
3. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
9. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
10. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
11. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):